Video

The Future of AI in Drug Discovery: How Artificial Intelligence is Generating Ideas for New Medicines

In this latest podcast episode from The Future Labs, Dr Jackie Hunter, our Board Director at BenevolentAI, explores how artificial intelligence is generating new ideas for new medicines, and cutting the time and cost of designing drugs to bring them to patients faster.

The development of new drugs and treatments is an extremely complicated and failure-prone process. As an example of the scale of the challenge - developing a drug and getting it to market can take 10-15 years and cost more than $2.5 billion. What’s more, the top selling drugs available today only work for 30-50% of the patients to whom they are prescribed.

Although technology has been an indispensable component of drug discovery for decades, patients are not yet authentically benefiting from its potential at it relates to the generation of  new and more effective treatments.

In this podcast, Jackie discuss how the high cost and decline in tangible outputs from drug R&D, has resulted in the need to seek out new inventive solutions to improve the efficiency of medicinal development. We explore a radically different approach - how building machine learning tools and applying artificial intelligence to drug discovery can create new ideas to be interpreted by scientists in the lab.

Listen to Jackie explain BenevolentAI’s approach to drug discovery and the progress we are making to better understand diseases and to develop treatments for the millions of patients that need them.

More Posts

You Might Also Like

Blog
Transforming drug discovery with AI: how we’re building and nurturing the best talent for the job
At BenevolentAI, we are on a mission to bring life-changing medicines to patients, and we are looking for collaborative, mission-driven people to join our tech, drug discovery and business operations teams in London, Cambridge and New York.
Oct 17, 2021
News
BenevolentAI identifies novel target for ulcerative colitis and advances candidate to IND/CTA-enabling studies
BenevolentAI’s AI-Drug Discovery platform uncovered a novel target not previously linked to ulcerative colitis and advanced candidate to preclinical studies.
Oct 14, 2021
Blog
Measuring bias: moving towards more inclusive health research outcomes #stateofai
Having shared our open-source Diversity Analysis Tool last year, we were tasked to investigate and demonstrate the lack of diversity in biomedical data as part of the State of AI Report 2021.
Oct 12, 2021
Blog
Expert-augmented computational drug discovery for rare diseases
Combining scientific expertise, computational tools and our AI-enhanced biomedical knowledge graph to successfully uncover a new drug combination for treating a rare brain cancer in children.
Sep 28, 2021
News
BenevolentAI appoints Dr John Orloff to its Board of Directors
Biopharmaceutical veteran Dr John Orloff joins the BenevolentAI Board as a Non-Executive Director as it scales the development of its leading AI-derived drug pipeline.
Sep 9, 2021
Blog
AI in Drug Discovery
This blog seeks to demystify the application of artificial intelligence (AI) and machine learning (ML) in drug discovery by exploring some of the challenges, opportunities and progress that has been achieved in the field so far.
Jul 13, 2021